[go: up one dir, main page]

WO2008136034A3 - Ophthalmic compositions for the treatment of ocular hypertension and glaucoma - Google Patents

Ophthalmic compositions for the treatment of ocular hypertension and glaucoma Download PDF

Info

Publication number
WO2008136034A3
WO2008136034A3 PCT/IT2008/000299 IT2008000299W WO2008136034A3 WO 2008136034 A3 WO2008136034 A3 WO 2008136034A3 IT 2008000299 W IT2008000299 W IT 2008000299W WO 2008136034 A3 WO2008136034 A3 WO 2008136034A3
Authority
WO
WIPO (PCT)
Prior art keywords
glaucoma
treatment
ocular hypertension
ophthalmic compositions
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2008/000299
Other languages
French (fr)
Other versions
WO2008136034A2 (en
Inventor
Daniele Sher
Grasso Letizia Gaetana Lo
Francesco Giuliano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIFI SpA
Original Assignee
SIFI SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIFI SpA filed Critical SIFI SpA
Publication of WO2008136034A2 publication Critical patent/WO2008136034A2/en
Publication of WO2008136034A3 publication Critical patent/WO2008136034A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of ophthalmic pharmaceutical compositions for the treatment of glaucoma and ocular hypertension. Particularly, the invention relates to ophthalmic formulations comprising a new active ingredient, optionally in combination with other active ingredients typically used in the treatment of ocular hypertension or glaucoma.
PCT/IT2008/000299 2007-05-04 2008-05-02 Ophthalmic compositions for the treatment of ocular hypertension and glaucoma Ceased WO2008136034A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2007A000890 2007-05-04
IT000890A ITMI20070890A1 (en) 2007-05-04 2007-05-04 OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

Publications (2)

Publication Number Publication Date
WO2008136034A2 WO2008136034A2 (en) 2008-11-13
WO2008136034A3 true WO2008136034A3 (en) 2008-12-24

Family

ID=39791437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000299 Ceased WO2008136034A2 (en) 2007-05-04 2008-05-02 Ophthalmic compositions for the treatment of ocular hypertension and glaucoma

Country Status (2)

Country Link
IT (1) ITMI20070890A1 (en)
WO (1) WO2008136034A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023421B1 (en) 2010-03-17 2021-09-14 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
CN111743882A (en) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 Semifluorinated compounds and compositions thereof
BR112019018688A2 (en) 2017-03-10 2020-04-07 Pfizer imidazo [4,5-c] quinoline derivatives as lrrk2 inhibitors
NZ760151A (en) * 2017-06-08 2025-11-28 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
CN112153970A (en) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 Ophthalmic composition containing tafluprost for the treatment of glaucoma
EP3982930A1 (en) 2019-06-11 2022-04-20 SIFI S.p.A. Microemulsion compositions
MX2022002667A (en) 2019-09-06 2022-04-07 Novaliq Gmbh OPHTHALMIC COMPOSITION FOR THE TREATMENT OF UVEITIS.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272810A1 (en) * 2004-06-04 2005-12-08 Eric Davis Compositions comprising nebivolol
WO2006113485A2 (en) * 2005-04-15 2006-10-26 Board Of Trustees Of Michigan State University Aminergic pharmaceutical compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272810A1 (en) * 2004-06-04 2005-12-08 Eric Davis Compositions comprising nebivolol
WO2006113485A2 (en) * 2005-04-15 2006-10-26 Board Of Trustees Of Michigan State University Aminergic pharmaceutical compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAN T Y K ET AL: "The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 35, no. 3, 1 June 1992 (1992-06-01), pages 387 - 395, XP023160607, ISSN: 0167-5273, [retrieved on 19920601] *
GALAMBOS: "Systemic Betablocker Treatment with Nebivolol enhances Ocular Hemodynamics in Glaucoma Patients with Arterial Hypertension", INVEST OPHTHALMOL VIS SCI, vol. 47, 2006, E-Abstract, pages 485, XP002499359 *
HOYNG P F J ET AL: "PHARMACOLOGICAL THERAPY FOR GLAUCOMA", DRUGS, ADIS INTERNATIONAL LTD, vol. 59, no. 3, 1 January 2000 (2000-01-01), pages 411 - 434, XP009014419, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
ITMI20070890A1 (en) 2008-11-05
WO2008136034A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX368377B (en) COMBINATION OF BRIMONIDINE and TIMOLOL FOR TOPICAL OPHTHALMIC USE.
WO2007127273A3 (en) Methods and compositions for altering cell function
MY143795A (en) Tetrahydropyridoindole derivatives
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2009007328A3 (en) Use of homo- and copolymers for stabilizing active ingredient formulations
WO2010109482A3 (en) Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
WO2006132647A3 (en) Antimicrobial copolymers and uses thereof
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
ATE456369T1 (en) FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
WO2010021607A3 (en) Pharmaceutical formulation
WO2008079993A3 (en) Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763851

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08763851

Country of ref document: EP

Kind code of ref document: A2